Advancing Personalized Medicine in Alzheimer's Disease: Liquid Biopsy Epigenomics Unveil <i>APOE</i> ε4-Linked Methylation Signatures.

ABSTRACT: Recent studies show that patients with Alzheimer's disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the Infinium^® MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including APOE ε4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and

SUBMITTER: Macias M 

PROVIDER: S-EPMC11989983 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature